BIOLOGY MEETS SILICON

Age Gracefully.
Age Well.

Building a new way to measure aging.

BioPyrexia is developing a semiconductor-manufactured organ-on-chip platform for aging biology and longevity research, integrating biological models with controlled microenvironments and advanced sensing.

ORGAN-ON-CHIP × INTEGRATED SENSING

THE OPPORTUNITY

Aging is measurable biology.

We are building toward controlled, human-relevant systems in which aging-associated biology can be interrogated through measurable cellular and tissue-level readouts.

Cellular aging

Investigate senescence, telomere maintenance and other aging-associated phenotypes.

Autophagy

Study cellular recycling and stress-response biology as measurable research endpoints.

Scalable measurement

Integrate sensing into the biological system to move toward more parallelized measurement.

THE PLATFORM

A semiconductor-manufactured tissue chip for aging biology.

BioPyrexia is developing a hybrid architecture combining optical access, microfluidics, biological interfaces and silicon-enabled structures and sensing.

THE SCIENCE

From mechanism to measurable readout.

The scientific focus connects cellular aging with SIRT1, autophagy and stress-response biology. These relationships remain subjects for experimental validation.

Longevity compoundSIRT1 / stress pathwaysAutophagyAging-associated readouts

FIRST APPLICATION

Longevity research and compound screening.

The initial application is a research platform for screening and characterizing compounds against defined aging-associated readouts.

Mechanism research

Investigate relationships among aging-associated pathways and cellular phenotypes.

Compound screening

Compare candidate compounds against defined biological readouts.

Translational research

Generate complementary evidence for future therapeutic research and development.

COLLABORATION

Let's build the next generation of aging biology tools.

We welcome conversations with pharmaceutical and biotechnology companies, researchers, engineering partners and investors.

Start a conversation